An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities

Antimicrobial Agents and Chemotherapy
Jason M PogueKimberly C Claeys

Abstract

Rapid diagnostic tests (RDTs) have revolutionized the management of Gram-negative bacteremia by allowing antimicrobial stewardship teams the ability to escalate therapy and improve patient outcomes through timely organism identification and detection of certain resistance determinants. However, given the complex nature of Gram-negative resistance, stewardship teams are left without clear direction for how to respond when resistance determinants are absent, as the safety of de-escalation in this setting is unknown. The primary purpose of this analysis was to determine the negative predictive values (NPVs) of resistance marker absence for predicting susceptibility in target bug-drug scenarios at two geographically distinct institutions. A total of 1,046 Gram-negative bloodstream isolates that were analyzed with the Verigene BC-GN platform were assessed. Except for Pseudomonas aeruginosa, the absence of resistance determinants as reported by the RDT largely predicted susceptibility to target antibiotics at both institutions. NPVs for ceftriaxone susceptibility in Escherichia coli and Klebsiella pneumoniae in the absence of either CTX-M or a carbapenemase gene were 98% and 93 to 94%, respectively. Similar results were seen with oth...Continue Reading

References

Feb 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David M Livermore
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Nov 3, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tristan T TimbrookKerry L LaPlante
May 24, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K R RivardE Neuner
Feb 17, 2018·Diagnostic Microbiology and Infectious Disease·Kimberly C ClaeysJ Kristie Johnson

❮ Previous
Next ❯

Citations

Jan 15, 2019·Expert Review of Molecular Diagnostics·Grégory DubourgFlorence Fenollar
Oct 13, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-Ralph ZaharFrançois Barbier
Oct 23, 2019·The Journal of Applied Laboratory Medicine·Rosemary C She, Jeffrey M Bender
Nov 18, 2019·Current Infectious Disease Reports·David A ButlerEric Wenzler
Oct 15, 2019·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D R GiacobbeG M Rossolini
May 18, 2021·Therapeutic Advances in Infectious Disease·Kenneth P KlinkerKarri A Bauer
Jun 17, 2021·Pharmacotherapy·Jamie L WagnerLauren R Biehle
Mar 28, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kimberly C ClaeysSurbhi Leekha
Dec 2, 2019·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Rama NasefFernanda Bonilla
Apr 10, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-H KimM-D Oh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.